Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 10:9:73-83.
doi: 10.2147/CMAR.S94059. eCollection 2017.

New developments in the management of Waldenström macroglobulinemia

Jithma P Abeykoon  1 , Uday Yanamandra  2 , Prashant Kapoor  3
Affiliations
Review

New developments in the management of Waldenström macroglobulinemia

Jithma P Abeykoon et al. Cancer Manag Res. .

Abstract

Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton's tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada.

Keywords: CXCR4; MYD88; ibrutinib; indolent lymphoma; lymphoplasmacytic lymphoma; management.

PubMed Disclaimer

Conflict of interest statement

Disclosure Research funding has been provided to the institution from Celgene, Takeda and Amgen for studies, in which Prashant Kapoor is a principal investigator. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia — a new syndrome? J Intern Med. 1944;117(3–4):216–247.
    1. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169(1):81–89. - PubMed
    1. Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013;88(1):60–65. - PMC - PubMed
    1. Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625–1626. - PubMed
    1. Olszewski AJ, Treon SP, Castillo JJ. Evolution of management and outcomes in Waldenstrom macroglobulinemia: a population-based analysis. Oncologist. 2016 Jul 29; Epub. - PMC - PubMed

LinkOut - more resources